Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LUCD OTCMKTS:PEYE NASDAQ:PROF NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCDLucid Diagnostics$1.08+1.4%$1.11$0.73▼$1.80$116.62M1.241.06 million shs1.19 million shsPEYEPrecision Optics$0.00$1.61▼$2.69$32.98M0.419,793 shs113,500 shsPROFProfound Medical$4.06-0.7%$5.11$3.76▼$9.17$122.71M0.5577,082 shs25,736 shsRCELAvita Medical$6.44-4.8%$5.13$3.60▼$14.16$171.69M1.58389,590 shs771,043 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCDLucid Diagnostics+2.91%-13.82%+3.92%-13.82%+25.27%PEYEPrecision Optics0.00%0.00%0.00%0.00%0.00%PROFProfound Medical+1.24%-0.49%-3.76%-39.76%-47.02%RCELAvita Medical+48.25%+60.57%+20.07%+29.75%-34.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCDLucid Diagnostics$1.08+1.4%$1.11$0.73▼$1.80$116.62M1.241.06 million shs1.19 million shsPEYEPrecision Optics$0.00$1.61▼$2.69$32.98M0.419,793 shs113,500 shsPROFProfound Medical$4.06-0.7%$5.11$3.76▼$9.17$122.71M0.5577,082 shs25,736 shsRCELAvita Medical$6.44-4.8%$5.13$3.60▼$14.16$171.69M1.58389,590 shs771,043 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCDLucid Diagnostics+2.91%-13.82%+3.92%-13.82%+25.27%PEYEPrecision Optics0.00%0.00%0.00%0.00%0.00%PROFProfound Medical+1.24%-0.49%-3.76%-39.76%-47.02%RCELAvita Medical+48.25%+60.57%+20.07%+29.75%-34.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUCDLucid Diagnostics 3.00Buy$3.65242.72% UpsidePEYEPrecision Optics 0.00N/AN/AN/APROFProfound Medical 3.00Buy$11.00169.61% UpsideRCELAvita Medical 2.40Hold$11.6085.39% UpsideCurrent Analyst Ratings BreakdownLatest PEYE, PROF, RCEL, and LUCD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.009/5/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $2.509/5/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $14.008/13/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/11/2025RCELAvita MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $8.008/8/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $18.008/8/2025RCELAvita MedicalBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$3.007/16/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUCDLucid Diagnostics$4.35M26.56N/AN/A($0.78) per share-1.37PEYEPrecision Optics$15.68M0.00N/AN/A$0.53 per share0.00PROFProfound Medical$11.84M10.38N/AN/A$2.01 per share2.03RCELAvita Medical$74.88M2.22N/AN/A$0.17 per share36.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUCDLucid Diagnostics-$45.53M-$1.19N/AN/AN/A-1,476.35%N/A-120.43%11/12/2025 (Estimated)PEYEPrecision Optics-$930K-$0.06N/AN/AN/A-5.93%-12.10%-6.41%N/APROFProfound Medical-$27.82M-$1.46N/AN/AN/A-343.97%-89.74%-73.06%11/6/2025 (Estimated)RCELAvita Medical-$61.85M-$1.97N/AN/AN/A-68.87%-632.62%-71.52%11/6/2025 (Estimated)Latest PEYE, PROF, RCEL, and LUCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 million$2.21 million8/7/2025Q2 2025RCELAvita Medical-$0.26-$0.38-$0.12-$0.38$34.27 million$18.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLUCDLucid DiagnosticsN/AN/AN/AN/AN/APEYEPrecision OpticsN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUCDLucid DiagnosticsN/A1.151.13PEYEPrecision Optics0.231.420.76PROFProfound Medical0.118.537.07RCELAvita Medical9.390.580.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUCDLucid Diagnostics74.01%PEYEPrecision OpticsN/APROFProfound Medical47.86%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipLUCDLucid Diagnostics6.80%PEYEPrecision Optics22.70%PROFProfound Medical1.52%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLUCDLucid Diagnostics70108.48 million101.10 millionNo DataPEYEPrecision Optics8016.92 million13.08 millionNot OptionablePROFProfound Medical15030.12 million29.66 millionOptionableRCELAvita Medical13026.62 million25.87 millionOptionablePEYE, PROF, RCEL, and LUCD HeadlinesRecent News About These CompaniesAvita Medical's (RCEL) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 16 at 8:08 AM | marketbeat.comAVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmSeptember 15 at 5:45 PM | globenewswire.comD. Boral Capital Sticks to Their Buy Rating for Avita Medical (RCEL)September 14 at 6:50 PM | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 13 at 10:00 AM | prnewswire.comRCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law FirmSeptember 11, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 10, 2025 | globenewswire.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comRCEL Alert: Kirby McInerney LLP Encourages AVITA Medical, Inc. Investors to Inquire about InvestigationSeptember 9, 2025 | businesswire.comAVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comAvita Medical (NASDAQ:RCEL) Given New $14.00 Price Target at D. Boral CapitalSeptember 7, 2025 | americanbankingnews.com71,738 Shares in Avita Medical Inc. $RCEL Purchased by Nuveen LLCSeptember 6, 2025 | marketbeat.comBrokerages Set Avita Medical Inc. (NASDAQ:RCEL) Price Target at $12.40September 6, 2025 | americanbankingnews.comAvita Medical says data shows hospital stay reduction with RCELL SystemSeptember 4, 2025 | msn.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmSeptember 4, 2025 | globenewswire.comAvita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 4, 2025 | marketbeat.comAVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationSeptember 3, 2025 | globenewswire.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 3, 2025 | globenewswire.comWellington Management Group LLP Acquires Shares of 82,206 Avita Medical Inc. $RCELSeptember 3, 2025 | marketbeat.comAvita Medical (NASDAQ:RCEL) Director Robert Mcnamara Purchases 10,000 SharesAugust 30, 2025 | insidertrades.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 28, 2025 | globenewswire.comAVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTake Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025Buffett’s Wisdom Could Spell Trouble for Palantir ShortsBy Chris Markoch | August 26, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Time to Take Profits on Strategy Stock? 3 Reasons You ShouldBy Gabriel Osorio-Mazilli | September 1, 2025DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceBy Ryan Hasson | August 19, 2025PEYE, PROF, RCEL, and LUCD Company DescriptionsLucid Diagnostics NASDAQ:LUCD$1.08 +0.02 (+1.42%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Precision Optics OTCMKTS:PEYEPrecision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.Profound Medical NASDAQ:PROF$4.06 -0.03 (-0.73%) As of 03:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Avita Medical NASDAQ:RCEL$6.44 -0.33 (-4.81%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
